“…These infections pose therapeutic challenges and are associated with substantially longer duration of hospital stay, increased hospital cost, higher morbidity and mortality [5,12], particularly when the agents are Methicillin resistant S. aureus (MRSA), Extended spectrum beta lactamase (ESBL) producing Enterobacteriaceae and/or other agents collectively referred to as multidrug-resistant (MDR) [11,13,14]. Studies from developing countries have shown high level of resistance (ranging from 50 to 100%) to the commonly used antibiotics like ampicillin, trimethoprim – sulphamethoxazole, gentamicin, chloramphenicol and third generation cephalosporins among S. aureus, E. coli , and P. aeruginosa [8,15] as opposed to low rates of resistance ranging from 0-50% in developed countries [16]. In both settings however, substantial rates of resistance to oxacillin, erythromycin and clindamycin reported for S. aureus, ranged from 10-60% [8,9,15,16] whereas vancomycin (for S. aureus and other Gram-positive bacteria ), amikacin, piperacillin-tazobactam and imepenem (for E. coli , P. aeruginosa and other Gram-negative bacteria) showed resistant rates of less than 25% [17,18].…”